EXOTHERA Revenue and Competitors
Estimated Revenue & Valuation
- EXOTHERA's estimated annual revenue is currently $29.9M per year.
- EXOTHERA's estimated revenue per employee is $155,000
Employee Data
- EXOTHERA has 193 Employees.
- EXOTHERA grew their employee count by 9% last year.
EXOTHERA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 32 | -26% | N/A | N/A |
#2 | $510.1M | 1097 | 31% | $2B | N/A |
#3 | $13.6M | 88 | 44% | N/A | N/A |
#4 | $12.2M | 79 | -17% | N/A | N/A |
#5 | $27.4M | 177 | -6% | N/A | N/A |
#6 | $29.9M | 193 | 9% | N/A | N/A |
#7 | $4.5M | 29 | -6% | N/A | N/A |
What Is EXOTHERA?
Exothera is a viral vector contract manufacturing and development organization (CDMO) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing.
keywords:N/AN/A
Total Funding
193
Number of Employees
$29.9M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EXOTHERA News
The scale-up manufacturing process will leverage Exothera's expertise using the NevoLi-ne Upstream platform (integrating the intensified...
ReiThera and Exothera are partnering to develop what they call a large-scale, low cost per dose manufacturing process to deliver novel...
ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $29.9M | 193 | 9% | N/A |
#2 | $105.3M | 581 | 16% | N/A |